Literature DB >> 6101295

Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 9. Nadolol: a new long-acting beta-adrenoceptor blocking drug.

W Frishman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6101295     DOI： 10.1016/0002-8703(80)90322-1

Source DB:  PubMed          Journal:  Am Heart J        ISSN： 0002-8703            Impact factor:   4.749


× No keyword cloud information.
  5 in total

1.  Effect of orally administered nadolol on the intraocular pressure in normal volunteers.

Authors:  J Williamson; H R Atta; P A Kennedy; J G Muir
Journal:  Br J Ophthalmol       Date:  1985-01       Impact factor: 4.638

2.  Nadolol in essential hypertension: effect on ambulatory blood pressure, renal haemodynamics and cardiac function.

Authors:  A G Dupont; P Vanderniepen; A M Bossuyt; M H Jonckheer; R O Six
Journal:  Br J Clin Pharmacol       Date:  1985-08       Impact factor: 4.335

3.  Role of sympathetic nervous system in non-ischaemic ventricular arrhythmias.

Authors:  P Coumel; M D Rosengarten; J F Leclercq; P Attuel
Journal:  Br Heart J       Date:  1982-02

4.  Pharmacokinetics of carteolol in relation to renal function.

Authors:  G Hasenfuss; M Schäfer-Korting; H Knauf; E Mutschler; H Just
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Noradrenergic signaling in the wakeful state inhibits microglial surveillance and synaptic plasticity in the mouse visual cortex.

Authors:  Rianne D Stowell; Grayson O Sipe; Ryan P Dawes; Hanna N Batchelor; Katheryn A Lordy; Brendan S Whitelaw; Mark B Stoessel; Jean M Bidlack; Edward Brown; Mriganka Sur; Ania K Majewska
Journal:  Nat Neurosci       Date:  2019-10-21       Impact factor: 24.884
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.